XVIVO Perfusion

XVIVO.ST Mid Cap

Healthcare · Medical Devices

Updated: Apr 5, 2026, 17:43 UTC

$240.20

-2.28% today

52W: $160.00 – $338.00

52W Low: $160.00 Position: 45.1% 52W High: $338.00

🔗 Compare Brokers

Key Metrics

P/E Ratio

304.05x

Price-to-Earnings

Forward P/E

40.64x

Forward Price/Earnings

P/S Ratio

9.32x

Price-to-Sales

EV/EBITDA

53.43x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$7.6B

Market Capitalization

Revenue Growth

-0.6%

YoY Revenue Growth

Profit Margin

3.1%

Net profit margin

ROE

1.18%

Return on Equity

Beta

1.4

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

161,066

Average daily volume

Valuation Analysis

Signal

Overvalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

5 analysts

Avg. Price Target

$302.00

+25.73% upside

Target Range

$245.00 – $385.00

About the Company

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isol

Sector: Healthcare Industry: Medical Devices Country: Sweden Employees: 198 Exchange: STO